ProCE Banner Activity

In HER2-Positive Early Breast Cancer, Who Benefits From Dual HER2-Targeted Therapy? Identifying High-Risk Disease

Clinical Thought
A closer look at the subset analysis of the APHINITY trial suggests that we still don’t know which patients with HER2-positive early breast cancer benefit from adding pertuzumab to trastuzumab. More research is needed.

Released: October 17, 2018

Expiration: October 16, 2019

No longer available for credit.

Share

Faculty

Mark D. Pegram

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech TEXT Only

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Mark D. Pegram, MD, has disclosed that he has received consulting fees from Genentech and Puma.